{
    "hands_on_practices": [
        {
            "introduction": "A key advantage of modern gene-based vaccine platforms, such as those using messenger RNA (mRNA), is their ability to use the host's cellular machinery to produce antigens in vivo. To rationally design and compare such vaccines, it is essential to model the dynamics of this antigen expression. This exercise provides a quantitative framework for understanding how the initial dose and stability of an mRNA vaccine translate into the total amount of antigen produced over time, a crucial factor driving the magnitude of the resulting immune response. ",
            "id": "4683819",
            "problem": "In a simplified model of an in vivo messenger ribonucleic acid (mRNA) vaccine platform, assume that the intracellular mRNA payload per target cell decays by first-order kinetics due to degradation and clearance, and that protein translation is linear in the instantaneous mRNA abundance. Specifically, let $M(t)$ denote the number of mRNA molecules per cell at time $t$ after delivery, with $M(0)=D$, and assume $dM/dt$ follows first-order loss with a constant rate $ \\delta $. Let the instantaneous protein synthesis rate (molecules per cell per hour) be $E(t)$, proportional to $M(t)$ with a constant translation efficiency $ \\alpha $.\n\nUsing only these assumptions and core definitions, first derive an explicit expression for $E(t)$ as a function of $D$, $ \\delta $, and $t$, and then derive the total cumulative number of protein molecules produced per cell over the window $[0, T]$, as a function of $D$, $ \\delta $, $ \\alpha $, and $T$. Finally, evaluate this cumulative production for $ \\alpha = 40$ proteins per mRNA per hour, $ D = 500$ mRNA molecules per cell at $t=0$, $ \\delta = 0.2$ hour$^{-1}$, and $ T = 24$ hours. Round your final numerical result to four significant figures and express it in proteins per cell.",
            "solution": "The problem statement is validated as scientifically grounded, well-posed, objective, and complete. The model, while a simplification, is based on standard principles of pharmacokinetics and molecular biology, specifically first-order decay and linear response. All necessary parameters and relationships are provided to derive a unique, meaningful solution.\n\nThe solution proceeds in three parts as requested: derivation of the protein synthesis rate $E(t)$, derivation of the cumulative protein production, and numerical evaluation for the given parameters.\n\n**Part 1: Derivation of mRNA Abundance $M(t)$ and Protein Synthesis Rate $E(t)$**\n\nThe problem states that the intracellular mRNA payload, $M(t)$, decays by first-order kinetics with a rate constant $\\delta$. This is described by the linear ordinary differential equation:\n$$\n\\frac{dM}{dt} = -\\delta M(t)\n$$\nThis is a separable differential equation, which can be rearranged and integrated:\n$$\n\\int \\frac{1}{M} dM = \\int -\\delta dt\n$$\nIntegrating both sides yields:\n$$\n\\ln(M(t)) = -\\delta t + C\n$$\nwhere $C$ is the constant of integration. Exponentiating both sides gives:\n$$\nM(t) = \\exp(-\\delta t + C) = \\exp(C) \\exp(-\\delta t)\n$$\nWe define a new constant $M_0 = \\exp(C)$ which represents the initial number of mRNA molecules at $t=0$. The problem provides the initial condition $M(0)=D$. Substituting $t=0$ into the equation:\n$$\nM(0) = M_0 \\exp(-\\delta \\times 0) = M_0 \\exp(0) = M_0\n$$\nTherefore, $M_0 = D$. The explicit expression for the number of mRNA molecules per cell at time $t$ is:\n$$\nM(t) = D \\exp(-\\delta t)\n$$\nNext, the problem defines the instantaneous protein synthesis rate, $E(t)$, as being proportional to the instantaneous mRNA abundance, $M(t)$, with a constant of proportionality $\\alpha$, the translation efficiency.\n$$\nE(t) = \\alpha M(t)\n$$\nSubstituting the derived expression for $M(t)$ into this equation gives the explicit expression for $E(t)$ as a function of $D$, $\\delta$, and $t$:\n$$\nE(t) = \\alpha D \\exp(-\\delta t)\n$$\nThis is the first required result.\n\n**Part 2: Derivation of Cumulative Protein Production**\n\nThe total cumulative number of protein molecules produced per cell over the time interval $[0, T]$, which we denote as $P_{total}(T)$, is the definite integral of the synthesis rate $E(t)$ from $t=0$ to $t=T$.\n$$\nP_{total}(T) = \\int_{0}^{T} E(t) dt\n$$\nSubstituting the expression for $E(t)$ gives:\n$$\nP_{total}(T) = \\int_{0}^{T} \\alpha D \\exp(-\\delta t) dt\n$$\nSince $\\alpha$ and $D$ are constants with respect to time, they can be factored out of the integral:\n$$\nP_{total}(T) = \\alpha D \\int_{0}^{T} \\exp(-\\delta t) dt\n$$\nThe integral of the exponential function is $\\int \\exp(-\\delta t) dt = -\\frac{1}{\\delta} \\exp(-\\delta t)$. We evaluate this definite integral using the fundamental theorem of calculus:\n$$\nP_{total}(T) = \\alpha D \\left[ -\\frac{1}{\\delta} \\exp(-\\delta t) \\right]_{0}^{T}\n$$\n$$\nP_{total}(T) = \\alpha D \\left( \\left(-\\frac{1}{\\delta} \\exp(-\\delta T)\\right) - \\left(-\\frac{1}{\\delta} \\exp(-\\delta \\times 0)\\right) \\right)\n$$\n$$\nP_{total}(T) = \\alpha D \\left( -\\frac{1}{\\delta} \\exp(-\\delta T) + \\frac{1}{\\delta} \\exp(0) \\right)\n$$\nSince $\\exp(0)=1$, we can simplify the expression:\n$$\nP_{total}(T) = \\alpha D \\left( \\frac{1}{\\delta} - \\frac{1}{\\delta} \\exp(-\\delta T) \\right)\n$$\nFactoring out the $\\frac{1}{\\delta}$ term gives the final analytical expression for the total cumulative protein production:\n$$\nP_{total}(T) = \\frac{\\alpha D}{\\delta} (1 - \\exp(-\\delta T))\n$$\nThis is the second required result.\n\n**Part 3: Numerical Evaluation**\n\nThe problem requires a numerical evaluation for the following parameter values:\n- Translation efficiency, $\\alpha = 40$ proteins per mRNA per hour\n- Initial mRNA dose, $D = 500$ molecules per cell\n- Degradation rate, $\\delta = 0.2$ hour$^{-1}$\n- Time window, $T = 24$ hours\n\nWe substitute these values into the derived expression for $P_{total}(T)$:\n$$\nP_{total}(24) = \\frac{40 \\times 500}{0.2} (1 - \\exp(-0.2 \\times 24))\n$$\nFirst, calculate the pre-factor and the exponent:\n$$\n\\frac{\\alpha D}{\\delta} = \\frac{20000}{0.2} = 100000\n$$\n$$\n-\\delta T = -0.2 \\times 24 = -4.8\n$$\nNow, substitute these back into the equation:\n$$\nP_{total}(24) = 100000 \\times (1 - \\exp(-4.8))\n$$\nThe value of the exponential term is approximately $\\exp(-4.8) \\approx 0.0082297$.\n$$\nP_{total}(24) \\approx 100000 \\times (1 - 0.0082297)\n$$\n$$\nP_{total}(24) \\approx 100000 \\times 0.9917703\n$$\n$$\nP_{total}(24) \\approx 99177.03\n$$\nThe problem requires this result to be rounded to four significant figures. The first four significant digits are $9$, $9$, $1$, and $7$. The fifth digit is $7$, which is $\\geq 5$, so we round up the fourth digit.\n$$\n99177.03 \\approx 99180\n$$\nExpressed in standard scientific notation to explicitly show four significant figures, the result is $9.918 \\times 10^4$ proteins per cell.",
            "answer": "$$\n\\boxed{9.918 \\times 10^4}\n$$"
        },
        {
            "introduction": "Following vaccination, the induced antibody response naturally wanes over time. A central question in vaccinology is predicting the duration of protection, which depends on the peak antibody level achieved and its subsequent rate of decay. This practice employs a fundamental first-order kinetic model to derive an analytical expression for the duration of protection and to explore its sensitivity to the decay rate, providing critical insights into the long-term effectiveness of a vaccine. ",
            "id": "4683873",
            "problem": "A vaccine platform that induces long-lived plasma cells typically exhibits first-order decay of circulating immunoglobulin G (IgG) antibody titers after peak response. Assume that after a single immunization with no subsequent boosting, the antibody titer $A(t)$ follows a first-order kinetic model governed by the ordinary differential equation $\\,\\frac{dA}{dt}=-\\lambda A\\,$ with initial condition $A(0)=A_0$, where $A_0&gt;0$ is the peak titer and $\\lambda&gt;0$ is the decay rate constant determined by plasma cell attrition and catabolism. A correlate of protection study has established a protective threshold titer $T$ with $0&lt;T&lt;A_0$. Define the protection duration $t^{\\ast}&gt;0$ implicitly by the condition $A(t^{\\ast})=T$.\n\nStarting only from the stated kinetic model and initial condition, and without assuming any further approximations, derive a closed-form analytic expression for $t^{\\ast}$ in terms of $A_0$, $T$, and $\\lambda$. Then quantify the sensitivity of $t^{\\ast}$ to the decay rate parameter $\\lambda$ using the elasticity $E\\equiv\\frac{\\partial \\ln t^{\\ast}}{\\partial \\ln \\lambda}$ evaluated at fixed $A_0$ and $T$. Provide both results as closed-form expressions. Express $t^{\\ast}$ in days if $\\lambda$ is in $\\text{day}^{-1}$. No numerical values are required.",
            "solution": "The problem requires deriving the protection duration $t^{\\ast}$ and its elasticity $E$ with respect to the decay rate $\\lambda$.\n\n**Part 1: Derivation of Protection Duration $t^{\\ast}$**\n\nThe antibody titer $A(t)$ follows the first-order decay model:\n$$ \\frac{dA}{dt} = -\\lambda A $$\nThis is a separable linear ordinary differential equation. We solve it with the initial condition $A(0) = A_0$:\n$$ \\int_{A_0}^{A(t)} \\frac{dA'}{A'} = \\int_{0}^{t} -\\lambda dt' $$\n$$ \\ln(A(t)) - \\ln(A_0) = -\\lambda t $$\n$$ \\ln\\left(\\frac{A(t)}{A_0}\\right) = -\\lambda t $$\nExponentiating both sides gives the solution for $A(t)$:\n$$ A(t) = A_0 \\exp(-\\lambda t) $$\nThe protection duration $t^{\\ast}$ is defined by the condition $A(t^{\\ast}) = T$, where $T$ is the protective threshold. We substitute this into the equation:\n$$ T = A_0 \\exp(-\\lambda t^{\\ast}) $$\nNow, we solve for $t^{\\ast}$:\n$$ \\frac{T}{A_0} = \\exp(-\\lambda t^{\\ast}) $$\nTaking the natural logarithm of both sides:\n$$ \\ln\\left(\\frac{T}{A_0}\\right) = -\\lambda t^{\\ast} $$\nUsing the logarithmic identity $\\ln(x/y) = -\\ln(y/x)$:\n$$ -\\ln\\left(\\frac{A_0}{T}\\right) = -\\lambda t^{\\ast} $$\nFinally, isolating $t^{\\ast}$ gives the first required closed-form expression:\n$$ t^{\\ast} = \\frac{1}{\\lambda} \\ln\\left(\\frac{A_0}{T}\\right) $$\nThe conditions $A_0 > T > 0$ ensure that $\\ln(A_0/T)$ is positive, and since $\\lambda > 0$, $t^{\\ast}$ is also positive, which is physically consistent. If $\\lambda$ is in units of $\\text{day}^{-1}$, then $t^{\\ast}$ will be in days.\n\n**Part 2: Derivation of Elasticity $E$**\n\nThe elasticity $E$ is defined as $E \\equiv \\frac{\\partial \\ln t^{\\ast}}{\\partial \\ln \\lambda}$. We first take the natural logarithm of the expression for $t^{\\ast}$:\n$$ \\ln(t^{\\ast}) = \\ln\\left(\\frac{1}{\\lambda} \\ln\\left(\\frac{A_0}{T}\\right)\\right) $$\nUsing the property $\\ln(ab) = \\ln(a) + \\ln(b)$:\n$$ \\ln(t^{\\ast}) = \\ln\\left(\\frac{1}{\\lambda}\\right) + \\ln\\left(\\ln\\left(\\frac{A_0}{T}\\right)\\right) $$\n$$ \\ln(t^{\\ast}) = -\\ln(\\lambda) + \\ln\\left(\\ln\\left(\\frac{A_0}{T}\\right)\\right) $$\nNow, we differentiate $\\ln(t^{\\ast})$ with respect to $\\ln(\\lambda)$. Since $A_0$ and $T$ are held constant, the term $\\ln\\left(\\ln\\left(\\frac{A_0}{T}\\right)\\right)$ is a constant with respect to $\\lambda$.\n$$ E = \\frac{\\partial}{\\partial \\ln \\lambda} \\left[ -\\ln(\\lambda) + \\ln\\left(\\ln\\left(\\frac{A_0}{T}\\right)\\right) \\right] $$\n$$ E = -\\frac{\\partial \\ln(\\lambda)}{\\partial \\ln \\lambda} + \\frac{\\partial}{\\partial \\ln \\lambda} \\left[ \\text{constant} \\right] $$\n$$ E = -1 + 0 $$\n$$ E = -1 $$\nThis result means that the protection duration has a constant elasticity of $-1$ with respect to the decay rate. This implies that a given percentage increase in the decay rate $\\lambda$ leads to the same percentage decrease in the protection duration $t^{\\ast}$.",
            "answer": "$$\\boxed{\\begin{pmatrix} \\frac{1}{\\lambda} \\ln\\left(\\frac{A_0}{T}\\right) & -1 \\end{pmatrix}}$$"
        },
        {
            "introduction": "The definitive measure of a vaccine's success is its efficacy, as determined in a large-scale clinical trial. This exercise moves from theoretical modeling to the principles of clinical data analysis, demonstrating how to estimate vaccine efficacy and its statistical uncertainty from attack rates observed in vaccine and placebo groups. By calculating a confidence interval and considering the underlying assumptions, you will engage with the rigorous methods required to make a causal claim about a vaccine's protective effect in a population. ",
            "id": "4683831",
            "problem": "An individually randomized, double-blind clinical trial evaluates a candidate messenger ribonucleic acid (mRNA) vaccine against a respiratory viral pathogen over a single epidemic season. Participants are randomized in a $1:1$ ratio to vaccine or placebo. Let the infection outcome be binary over the common fixed follow-up window, so that the attack rate (AR) is identified with the cumulative risk over that window. In the vaccine arm, $n_v = 6000$ participants are observed, with $x_v = 120$ virologically confirmed infections. In the control arm, $n_c = 6000$ participants are observed, with $x_c = 400$ confirmed infections.\n\nUsing the conventional attack rate-based vaccine efficacy estimator derived from the risk ratio, compute a two-sided $95\\%$ confidence interval for vaccine efficacy that is justified from first principles of binomial sampling and large-sample asymptotics. Express the lower and upper bounds of the confidence interval as decimals in the interval $[0,1]$, and round both bounds to four significant figures. Provide your final answer as the ordered pair of bounds.\n\nAdditionally, in your derivation, explicitly state the assumptions under which this estimator identifies causal vaccine efficacy in this trial design and the conditions under which the large-sample confidence interval has nominal coverage. Do not use percentages in your final numerical answer and do not include any units.",
            "solution": "The problem requires the computation of a $95\\%$ confidence interval for vaccine efficacy (VE) and a discussion of the underlying assumptions.\n\n**Part 1: Calculation of the Confidence Interval for Vaccine Efficacy**\n\nFirst, we define the relevant parameters and their sample estimates. Let $p_v$ and $p_c$ be the true attack rates (risk of infection) in the vaccinated and control populations, respectively. The sample estimates are:\n-   Attack rate in vaccine group: $\\hat{p}_v = \\frac{x_v}{n_v} = \\frac{120}{6000} = 0.02$\n-   Attack rate in control group: $\\hat{p}_c = \\frac{x_c}{n_c} = \\frac{400}{6000} = \\frac{1}{15} \\approx 0.06667$\n\nVaccine efficacy is defined in terms of the risk ratio ($RR = p_v / p_c$):\n$$ VE = 1 - RR = 1 - \\frac{p_v}{p_c} $$\nThe point estimate for VE is:\n$$ \\widehat{VE} = 1 - \\widehat{RR} = 1 - \\frac{\\hat{p}_v}{\\hat{p}_c} = 1 - \\frac{0.02}{1/15} = 1 - 0.3 = 0.70 $$\n\nTo find the confidence interval for VE, we first find the confidence interval for the natural logarithm of the risk ratio, $\\ln(RR)$, because its sampling distribution is better approximated by a normal distribution for large samples. The standard error of $\\ln(\\widehat{RR})$ is estimated as:\n$$ \\widehat{SE}(\\ln(\\widehat{RR})) = \\sqrt{\\left(\\frac{1}{x_v} - \\frac{1}{n_v}\\right) + \\left(\\frac{1}{x_c} - \\frac{1}{n_c}\\right)} $$\nPlugging in the given numbers:\n$$ \\widehat{SE}(\\ln(\\widehat{RR})) = \\sqrt{\\left(\\frac{1}{120} - \\frac{1}{6000}\\right) + \\left(\\frac{1}{400} - \\frac{1}{6000}\\right)} $$\n$$ \\widehat{SE}(\\ln(\\widehat{RR})) = \\sqrt{0.0081666... + 0.0023333...} = \\sqrt{0.0105} \\approx 0.10247 $$\nA two-sided $95\\%$ confidence interval for $\\ln(RR)$ is given by $\\ln(\\widehat{RR}) \\pm z_{0.975} \\times \\widehat{SE}(\\ln(\\widehat{RR}))$. The critical value from the standard normal distribution is $z_{0.975} \\approx 1.96$. The point estimate is $\\ln(\\widehat{RR}) = \\ln(0.3) \\approx -1.20397$.\nThe bounds for the $95\\%$ CI for $\\ln(RR)$ are:\n-   Lower bound: $-1.20397 - 1.96 \\times 0.10247 \\approx -1.20397 - 0.20084 = -1.40481$\n-   Upper bound: $-1.20397 + 1.96 \\times 0.10247 \\approx -1.20397 + 0.20084 = -1.00313$\n\nTo get the confidence interval for $RR$, we exponentiate these bounds:\n-   Lower bound for RR: $\\exp(-1.40481) \\approx 0.24541$\n-   Upper bound for RR: $\\exp(-1.00313) \\approx 0.36674$\n\nFinally, we transform the CI for $RR$ into a CI for $VE = 1 - RR$. This transformation reverses the bounds.\n-   Lower bound for VE: $1 - U_{RR} = 1 - 0.36674 = 0.63326$\n-   Upper bound for VE: $1 - L_{RR} = 1 - 0.24541 = 0.75459$\n\nRounding both bounds to four significant figures gives the final $95\\%$ confidence interval for vaccine efficacy: $[0.6333, 0.7546]$.\n\n**Part 2: Assumptions and Conditions**\n\n**Assumptions for Causal Identification of Vaccine Efficacy:**\nFor the estimator $\\widehat{VE} = 1 - \\widehat{RR}$ to identify the causal effect of the vaccine, the following assumptions, typical for a randomized controlled trial, must hold:\n1.  **Stable Unit Treatment Value Assumption (SUTVA)**: This includes (a) *no interference*, meaning one person's vaccination status does not affect another's risk of infection (e.g., no herd effects within the trial), and (b) *consistency*, meaning there is only one version of the treatment and placebo.\n2.  **Exchangeability**: Achieved by successful randomization, this ensures the vaccine and placebo groups are comparable on all baseline characteristics, both measured and unmeasured, so that any difference in outcomes can be attributed to the vaccine.\n3.  **Positivity**: Every participant has a non-zero probability of receiving either treatment, which is guaranteed by the trial design.\n4.  **No differential loss to follow-up and complete outcome ascertainment**: Drop-out rates and reasons must be independent of treatment assignment and outcome. All infections must be accurately and equally detected in both groups. Double-blinding is crucial for mitigating bias in reporting, testing, and case confirmation.\n\n**Conditions for Nominal Coverage of the Large-Sample Confidence Interval:**\nFor the calculated $95\\%$ confidence interval to have a true coverage probability of approximately $95\\%$, these statistical conditions must be met:\n1.  **Independent Observations**: The outcomes for all participants are independent events.\n2.  **Large-Sample Approximation**: The number of events in each arm ($x_v = 120$ and $x_c = 400$) must be sufficiently large for the sampling distribution of $\\ln(\\widehat{RR})$ to be well-approximated by a normal distribution, as justified by the Central Limit Theorem and the Delta method. This condition is clearly met here.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.6333 & 0.7546 \\end{pmatrix}}$$"
        }
    ]
}